Back to search

Article

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCAassociated vasculitis (COMBIVAS): design of the study protocol

2022-11-07

Abstract excerpt

<h4>Background: </h4> Sequential B cell targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) and may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. Study Design. COMBIVAS is a randomised, double blind, placebo-controlled trial designed to assess the mechanistic effects of sequential therapy of belimumab and rituximab in patients with act...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a6e13e17-8575-5cd6-9fa4-ebd648509f7f
DOI
10.21203/rs.3.rs-2138639/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCAassociated vasculitis (COMBIVAS): design of the study protocolDOI 10.21203/rs.3.rs-2138639/v1
Real world use of avacopan for ANCA-associated vasculitis. First experiences in Ireland.Semantic proximity
Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritisSemantic proximity
Investigation of novel therapeutic strategies in B cell and antibody mediated diseaseSemantic proximity
Real-World Effectiveness and Safety of Avacopan in ANCA-Associated Vasculitis: A Systematic Literature Review and Meta-analysisSemantic proximity
Efficacy and safety of belimumab in immune thrombocytopenia secondary to systemic lupus erythematosusSemantic proximity
Biologic therapies for lupus nephritis: a systematic review of efficacy, safety, and cost-effectivenessSemantic proximity
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapySemantic proximity
Exploration of Rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environmentSemantic proximity
Differences in phenotypes, treatments, and outcomes of ANCA-associated vasculitis across Europe, Japan and the USA in 2020.Semantic proximity
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA.Semantic proximity
ANCA-associated vasculitis following secukinumab treatment for psoriasis: Expanding the Spectrum of IL-17A Inhibitor-Related Autoimmunity— A Case ReportSemantic proximity
Systematic Review and Meta-analysis of Eculizumab, Inebilizumab, Tocilizumab, and Satralizumab for Neuromyelitis OpticaSemantic proximity
Select a neighboring publication to make it the new centre.